Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.42 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268236 | 0.84 | KMT2A (0.57) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL9523223 | 0.82 | KMT2A (0.55) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL2632922 | 0.81 | KMT2A (0.62) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL22303034 | 0.80 | KMT2A (0.53) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL27001165 | 0.79 | KMT2A (0.53) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL12035264 | 0.79 | KMT2A (0.53) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL26789473 | 0.79 | POLB (0.59) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL29244600 | 0.79 | KMT2A (0.49) | KMT2APOLBHSP90AA1HSP90AB1HPGDS | |
| SCHEMBL14116749 | 0.78 | HSD17B10 (0.41) | KMT2AALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL12499299 | 0.78 | KMT2A (0.47) | KMT2APOLBHSP90AA1HSP90AB1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492210-B2 | Tricyclic compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-12-09 | — | — | US | disclosed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| WO-2024137607-A1 | THIADIAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-117486888-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117486890-A | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2024-02-02 | — | — | CN | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-113966336-B | Tricyclic compounds and uses thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3980424-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | Hutchison Medipharma Limited (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-8129541-B2 | 5-phenylthiazole derivatives and use as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2011-12-22 | — | — | US | disclosed |
| WO-2010130034-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | BRUCE IAN | 2010-04-15 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-7687637-B2 | 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors | NOVARTIS AG (CH) | 2010-03-30 | — | — | US | disclosed |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | Board of Regents, The University of Texas System, a Texas University (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093690-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | PIK3CA, PIK3R5, PIP5K1B | KMT2A 2183/4885POLB 3369/4885HSP90AA1 2913/4885 |
| US-20220315597-A1 | TRICYCLIC COMPOUNDS AND THEIR USE | CYP2C8, CYP11B2, CYP3A7 | KMT2A 2391/4885POLB 1434/4885HSP90AA1 3887/4885 |
| US-20110312992-A1 | Inhibitors of C-Kit and Uses Thereof | KIT, CHUK, MASTL | KMT2A 773/4885POLB 2129/4885HSP90AA1 4360/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | KMT2A 2329/4885POLB 76/4885HSP90AA1 3237/4885 |
| US-12492210-B2 | Tricyclic compounds and their use | CYP2C8, CYP11B2, CYP3A7 | KMT2A 2391/4885POLB 1434/4885HSP90AA1 3887/4885 |
| US-20090281115-A1 | INHIBITORS OF C-KIT AND USES THEREOF | KIT, CHUK, MASTL | KMT2A 773/4885POLB 2129/4885HSP90AA1 4360/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | KMT2A 899/4885POLB 1849/4885HSP90AA1 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.